| Literature DB >> 27376309 |
Salla E Toikkanen1,2, Armin Baillot3, Johannes Dreesman4, Elke Mertens5.
Abstract
The number of asylum seekers arriving in Germany has increased rapidly since 2014 and cases of vaccine-preventable diseases at reception centres were reported. Asylum seekers 12 years and older arriving in Lower Saxony were serologically screened for antibodies against measles, rubella and varicella between November 2014 and October 2015. We calculated the seroprevalence from the screening data by disease, country of origin and age group and compared them to literature-based herd immunity thresholds in order to identify immunisation gaps. In total, 23,647 specimens were included in our study. Although the vast majority of asylum seekers tested positive for antibodies against measles, rubella and varicella, the seroprevalences were not sufficient to ensure herd immunity. The seroprevalences varied substantially between countries of origin and increased with age. Immunisation of asylum seekers against measles, rubella and varicella is needed and the detailed information on seroprevalences among subgroups of asylum seekers can be used for targeted immunisations at reception centres.Entities:
Keywords: IgG; asylum seekers; immunisation; measles; rubella; seroprevalence; varicella
Mesh:
Substances:
Year: 2016 PMID: 27376309 PMCID: PMC4962191 DOI: 10.3390/ijerph13070650
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Ten most frequently reported countries of origin among asylum seekers arriving in Lower Saxony, November 2014–October 2015.
| Country of Origin ( | No. | % |
|---|---|---|
| Syrian Arab Republic | 5135 | 21.8 |
| Iraq | 2822 | 12.0 |
| Montenegro | 2525 | 10.7 |
| Sudan | 2196 | 9.3 |
| Afghanistan | 1535 | 6.5 |
| Algeria | 1107 | 4.7 |
| Serbia | 1083 | 4.6 |
| Kosovo | 1045 | 4.4 |
| Albania | 799 | 3.4 |
| Ivory Coast | 632 | 2.7 |
Number of positive and tested samples and seroprevalence with 95% confidence intervals for measles, rubella and varicella antibodies.
| Sex | No. Positive | No. Tested | % Positive (95% CI) | |
|---|---|---|---|---|
| Measles | Male | 12,880 | 15,928 | 80.9 (80.2–81.5) |
| Female | 4030 | 5131 | 78.5 (77.4–79.7) | |
| Total | 18,896 | 23,647 | 79.9 (79.4–80.4) | |
| Rubella | Male | 13,907 | 15,926 | 87.3 (86.8–87.8) |
| Female | 4104 | 5129 | 80.0 (78.9–81.1) | |
| Total | 20,132 | 23,643 | 85.1 (84.7–85.6) | |
| Varicella | Male | 13,828 | 15,928 | 86.8 (86.3–87.3) |
| Female | 4610 | 5131 | 89.8 (89.0–90.7) | |
| Total | 20,693 | 23,647 | 87.5 (87.1–87.9) |
Number of positive and tested samples and seroprevalence with 95% confidence intervals for measles, rubella and varicella antibodies stratified by age group.
| Age Group | No. Positive | No. Tested | % Positive (95% CI) | |
|---|---|---|---|---|
| Measles | 12–29 | 11,328 | 15,121 | 74.9 (74.2–75.6) |
| 30–44 | 5682 | 6567 | 86.5 (85.7–87.3) | |
| 45– | 1886 | 1959 | 96.3 (95.3–97.1) | |
| Rubella | 12–29 | 12,600 | 15,119 | 83.3 (82.7–83.9) |
| 30–44 | 5803 | 6567 | 88.4 (87.6–89.1) | |
| 45– | 1729 | 1957 | 88.3 (86.8–89.7) | |
| Varicella | 12–29 | 12,835 | 15,121 | 84.9 (84.3–85.4) |
| 30–44 | 6011 | 6567 | 91.5 (90.8–92.2) | |
| 45– | 1847 | 1959 | 94.3 (93.2–95.3) |
Figure 1Seroprevalence by country of origin with 95% confidence intervals: (a) Measles; (b) Rubella; (c) Varicella. The dotted lines mark the herd immunity thresholds (95% for measles and rubella, 91% for varicella [8,9,10,11]).
Figure 2Seroprevalence by country of origin and age group (12–29 years, 30–44 years, 45 years and older) with 95% confidence intervals: (a) Measles; (b) Rubella; (c) Varicella. The dotted lines mark the herd immunity thresholds (95% for measles and rubella, 91% for varicella [8,9,10,11]).
Results from multivariable logistic regression models with the seropositivity status (Yes/No) as dependent variable and sex, age and country of origin as independent variables. The output for countries of origin is omitted.
| Factor | OR (95% CI) | Z-Statistic | |||
|---|---|---|---|---|---|
| Measles | Sex | Female | (Ref.) | ||
| Male | 1.01 (0.93–1.10) | 0.24 | 0.813 | ||
| Age | 1.06 (1.06–1.07) | 27.7 | <0.001 | ||
| Rubella | Sex | Female | (Ref.) | ||
| Male | 1.32 (1.20–1.44) | 6.03 | <0.001 | ||
| Age | 1.03 (1.03–1.04) | 15.2 | <0.001 | ||
| Varicella | Sex | Female | (Ref.) | ||
| Male | 1.03 (0.92–1.15) | 0.54 | 0.590 | ||
| Age | 1.04 (1.03–1.04) | 13.3 | <0.001 | ||